Every Form 4 that Protara Therapeutics, Inc. (TARA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TARA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARA filings page.
Protara Therapeutics, Inc. CEO Jesse Shefferman reported multiple equity transactions in Protara common stock. On June 29, 2026, he exercised stock options to acquire 215,687 shares at an exercise price of $1.91 per share and sold 215,687 shares in open-market transactions at a weighted average price of $4.09 per share, with individual sale prices ranging from $4.03 to $4.14.
On June 30, 2026, Shefferman made bona fide gift transfers totaling 30,000 shares of common stock in four separate transactions. Following these transactions, he holds 691,832 shares directly and 300,000 shares indirectly through The Samhold Family Trust, and 141,313 stock options with a $1.91 exercise price expiring on January 18, 2034.
Protara Therapeutics director Richard S. Levy received a stock option grant covering 31,000 shares of common stock. The option has an exercise price of $3.94 per share and was granted as a derivative security.
According to the terms, the 31,000 options are scheduled to vest in full on the first anniversary of the grant date, provided Dr. Levy continues to serve on the board through that date. The options will also vest in full upon a Change of Control. Following this grant, his reported derivative holdings from this award total 31,000 options.
Protara Therapeutics director Michael Edward Solomon received a stock option grant for 31,000 shares of Common Stock. The option has an exercise price of $3.94 per share and was granted as a Stock Option (Right to Buy). It vests in full on the first anniversary of the grant date, subject to his continued service on the Board, and will also vest in full upon a Change of Control. Following this award, he holds 31,000 option shares related to this grant, which expires on June 14, 2036.
Protara Therapeutics director Cynthia Smith received a grant of stock options as equity compensation. She was awarded options covering 31,000 shares of common stock at an exercise price of $3.94 per share. These options vest in full on the first anniversary of the grant date, provided she continues to serve on the board, and will also fully vest upon a Change of Control.
Protara Therapeutics director Gregory Sargen received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and will vest in full on the first anniversary of the June 15, 2026 grant date, or upon a Change of Control, subject to his continued Board service. Following this award, the filing shows 31,000 derivative securities held directly.
Protara Therapeutics director Jane Huang received a stock option grant for 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036. The entire Annual Grant vests on the first anniversary of the June 15, 2026 grant date, subject to her continued board service, and also fully vests upon a Change of Control.
Protara Therapeutics director Roger Garceau received a grant of stock options for 31,000 shares of Common Stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, subject to continued board service.
Protara Therapeutics director Barry P. Flannelly received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036.
According to the grant terms, the 31,000 options vest in full on the first anniversary of the June 15, 2026 grant date, as long as the director continues serving on the board, and they vest in full upon a Change of Control.
Protara Therapeutics director Luke M. Beshar received a grant of stock options covering 31,000 shares of common stock. These options have an exercise price of $3.94 per share and were awarded as compensation, not purchased in the open market.
The options were granted as an Annual Grant and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board through that date. They will also vest in full upon a Change of Control, if that occurs earlier.
Protara Therapeutics, Inc. Chief Commercial Officer William Conkling reported a routine tax-related share disposition. On June 2, 2026, 6,008 shares of common stock were withheld by the company at $4.34 per share to cover income tax obligations from the vesting of Restricted Stock Unit Awards granted on June 2, 2025. After this withholding, Conkling directly holds 69,992 shares of Protara common stock. This transaction was not an open-market purchase or sale, but an administrative step tied to equity compensation.
Protara Therapeutics, Inc. Chief R&D Officer Jacqueline Zummo sold 1,134 shares of Common Stock on April 8, 2026 at $5.40 per share in an open-market transaction. The sale occurred automatically under a Rule 10b5-1 trading plan established on December 31, 2025. Following the sale, she directly holds 94,827 shares.
Protara Therapeutics Chief R&D Officer sells shares under trading plan. Jacqueline Zummo completed an open-market sale of 22,598 shares of Protara Therapeutics common stock at a weighted average price of $5.26 per share. After this automatic sale under a Rule 10b5-1 trading plan established on December 31, 2025, she directly holds 95,961 shares.
Protara Therapeutics VP, Controller Hannah Fry reported a tax-related share withholding. On 01/26/2026, 1,457 shares of Protara Therapeutics common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 24, 2025. After this withholding, Fry beneficially owned 42,723 shares of Protara common stock in direct ownership.
Protara Therapeutics, Inc. Chief Financial Officer Patrick Fabbio reported an automatic share withholding related to equity compensation. On 01/26/2026, 3,261 shares of common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations arising from the vesting of a previously granted restricted stock unit award. After this tax withholding, Fabbio directly beneficially owns 64,115 shares of Protara common stock.
Protara Therapeutics CEO and President Jesse Shefferman, a director of Protara Therapeutics, Inc. (TARA), reported a routine share withholding related to equity compensation. On January 26, 2026, the company withheld 8,732 shares of common stock at $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award granted on January 24, 2025. After this tax withholding, Shefferman beneficially owns 1,021,832 shares of Protara common stock directly.
Protara Therapeutics reported an insider share withholding by its Chief Scientific Operations Officer, Jacqueline Zummo. On January 26, 2026, 3,724 shares of common stock were withheld at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award that was granted on January 24, 2025. After this tax-related transaction, Zummo beneficially owns 118,559 shares of Protara common stock directly.
Protara Therapeutics, Inc. CEO and President Jesse Shefferman reported a Form 4 transaction involving company common stock. On January 20, 2026, 16,322 shares of Protara Therapeutics common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations tied to previously granted restricted stock unit awards that vested. After this tax withholding, Shefferman beneficially owned 1,030,564 shares of Protara common stock directly.
Protara Therapeutics Chief Financial Officer reports tax-related share withholding. On January 20, 2026, CFO Patrick Fabbio had 3,063 shares of common stock withheld by Protara Therapeutics to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 19, 2024. The shares were treated as a disposition at $5.60 per share, and Fabbio now directly holds 67,376 shares of Protara Therapeutics common stock after this administrative transaction.
Protara Therapeutics, Inc. officer Jacqueline Zummo reported a tax-related share withholding transaction. On January 20, 2026, 6,578 shares of Protara common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards granted to her in January 2023 and January 2024.
After this withholding, Zummo directly beneficially owned 122,283 shares of Protara common stock. The filing characterizes the event as an automatic share withholding for taxes rather than an open-market sale.
Protara Therapeutics VP and Controller Hannah Fry reported a routine share withholding related to equity compensation. On January 20, 2026, the company withheld 2,132 shares of common stock at a value of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards originally granted on January 19, 2023 and January 19, 2024. After this tax-related transaction, Fry beneficially owned 44,180 shares of Protara Therapeutics common stock in direct ownership.
Protara Therapeutics reported new equity awards for its Chief Commercial Officer, William Conkling. On January 16, 2026, he received 26,000 shares of common stock at no cost, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, as long as he remains with the company.
He was also granted stock options covering 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. For these options, 25% of the shares vest on the one-year anniversary of January 16, 2026, and the remaining 75% vest in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 76,000 common shares and 158,000 options.
Protara Therapeutics Chief Financial Officer Patrick Fabbio reported new equity awards in the company. On January 16, 2026, he received 28,000 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second and third anniversaries of January 16, 2026, as long as he remains in continuous service. After this grant, he directly beneficially owned 70,439 shares of common stock.
On the same date, he was also granted 175,000 stock options with an exercise price of $5.01 per share. For these options, 25% vest on the one-year anniversary of January 16, 2026, and the remaining portion vests in equal monthly installments over the following three years, also conditioned on continued service. Following this grant, he directly held 175,000 stock options in total.
Protara Therapeutics VP and Controller Hannah Fry reported new equity awards. On January 16, 2026, she received 9,500 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, contingent on her continued service.
Fry was also granted a stock option for 55,000 shares of common stock with an exercise price of $5.01 per share, expiring on January 15, 2036. According to the award terms, 25% of these option shares vest on the one-year anniversary of January 16, 2026, and the remainder vest in equal monthly installments over the following three years, subject to continued service. After the RSU grant, she beneficially owned 46,312 common shares directly, and 55,000 options.
Protara Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, Nicacio Leonardo Viana. On January 16, 2026, he received stock options for 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. These options vest with 25% of the shares on the one-year anniversary of January 16, 2026, and the remaining shares vest in monthly installments over the following three years, conditioned on continued service.
He also acquired 26,000 shares of common stock at a price of $0 pursuant to restricted stock unit awards. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, also subject to continued service. Following these awards, he beneficially owns 78,181 shares of common stock directly, in addition to the unexercised options.
Protara Therapeutics CEO and President Jesse Shefferman reported new equity awards. On January 16, 2026, he received 87,000 shares of common stock at a price of $0 pursuant to restricted stock unit (RSU) awards, bringing his directly held common shares to 1,046,886.
He was also granted stock options covering 524,000 shares of common stock at an exercise price of $5.01 per share, with 524,000 derivative securities held directly after the grant. The RSUs vest in three equal annual installments on the first, second, and third anniversaries of January 16, 2026, contingent on his continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in equal monthly installments over the next three years, also subject to continued service, and expire on January 15, 2036.
Protara Therapeutics reported an equity compensation grant to its Chief Scientific Operations Officer, Jacqueline Zummo. On January 16, 2026, she received 30,000 shares of common stock for $0, issued pursuant to restricted stock unit awards. Following this grant, she beneficially owned 128,861 common shares directly.
The filing also shows a grant of 180,000 stock options with a $5.01 exercise price, recorded at a $0 acquisition cost. The RSUs vest in three equal annual installments on the first, second and third anniversaries of January 16, 2026, contingent on continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in 1/48th monthly installments over the next three years, also conditioned on ongoing service.